0001649094-24-000054.txt : 20240820
0001649094-24-000054.hdr.sgml : 20240820
20240820164955
ACCESSION NUMBER: 0001649094-24-000054
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240819
FILED AS OF DATE: 20240820
DATE AS OF CHANGE: 20240820
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GUGGENHIME ANDREW
CENTRAL INDEX KEY: 0001230724
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 241225905
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
wk-form4_1724186989.xml
FORM 4
X0508
4
2024-08-19
0
0001649094
Vaxcyte, Inc.
PCVX
0001230724
GUGGENHIME ANDREW
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS
CA
94070
0
1
0
0
PRESIDENT AND CFO
1
Common Stock
2024-08-19
4
M
0
8000
5.35
A
104720
D
Common Stock
2024-08-19
4
S
0
4994
78.248
D
99726
D
Common Stock
2024-08-19
4
S
0
3006
79.135
D
96720
D
Stock Option (right to buy)
5.35
2024-08-19
4
M
0
8000
0
D
2030-05-11
Common Stock
8000
328827
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $77.875 to $78.78. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $78.88 to $79.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.
1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.
Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact
2024-08-20